5 news items
Vivani Medical to Present at TIDES Conference 2024
VANI
9 May 24
and the planned development therefor, technology and strategy. Forward-looking statements are neither historical facts nor assurances of future performance
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VANI
26 Mar 24
the therapeutic potential thereof and the planned development therefor, technology and strategy. Forward-looking statements are neither historical
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
VANI
6 Mar 24
emerging development plans for NPM-115, NPM-139, or our plans with respect to Cortigent and its proposed initial public offering, technology, strategy
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
VANI
1 Mar 24
for NPM-115, NPM-139, or our plans with respect to Cortigent and its proposed initial public offering, technology, strategy, cash position
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
VANI
28 Feb 24
development plans for NPM-115, NPM-139, or our plans with respect to Cortigent and its proposed initial public offering, technology, strategy, cash position
- Prev
- 1
- Next